This article was released as Pharm Edaily Premium Content on June 12, 2026, at 8:00 AM.
[Yu Jin-hee, Edaily Reporter] While the South Korean stock market continues to see foreign and institutional capital heavily concentrated in the semiconductor sector, the biotechnology segment successfully held its ground on June 11, buoyed by clear clinical milestones and strong corporate governance. Investor sentiment is rapidly coalescing around enterprises backed by solid earnings momentum and proactive management efforts to restore market trust.
In particular, key anticipation stocks that demonstrated rigorous data validation and a commitment to responsible management stood out even amidst a broader market downturn. The three standout companies GI Innovation, Orient Bio, and L&C Bio all posted double-digit gains in overall market returns on the day, driving an upward rally for the bio sector by drawing in strong buying pressure.
|
In-Depth Evaluation: GI Innovation Soars on Revolutionary 'GI-101A' Data Validated at Global Top-Tier Oncology Conference
On the day, GI Innovation (358570) surged by 15.40% from the previous trading day on the KOSDAQ market, closing at 13,640 won and landing at the top of the bio sector's gainers list. This performance was driven by a combination of a bullish analysis report from a prominent U.S. healthcare investment bank (IB) and powerful momentum ahead of an upcoming oral presentation at the world’s largest cancer symposium, triggering a wave of institutional and foreign buy orders.
Recently, U.S. healthcare IB Leerink Partners highlighted GI Innovation’s next-generation immuno-oncology candidate, ‘GI-101A’, as a highly promising, market-disrupting program in its 'ASCO 2026' Immuno-Oncology Review Report. The report offered an in-depth analysis suggesting that while global oncology investment trends are currently overly skewed toward antibody-drug conjugates (ADCs) or VEGF/PD-1 bispecific antibodies, the true paradigm shift moving forward will be triggered in the Interleukin-2 (IL-2) bispecific fusion antibody (bs-fusion-Ab) space.
Positioned at the center of this mega-trend, GI-101A is scheduled for an oral presentation of its Phase 1/2 clinical trial results at the American Society of Clinical Oncology (ASCO 2026) annual meeting on May 30 (local time).
The presentation will be delivered by Dr. Jae-Lyun Lee, a global key opinion leader (KOL) in urologic oncology, drawing intense focus from global biopharma CEOs and business development (BD) executives. Out of numerous abstracts, the selection of an early-stage clinical dataset for an oral presentation session is a significant indicator that the global medical community values this core pipeline highly.
The pre-released abstract data exceeded market expectations. In the effective dose cohort (0.2–0.3 mg/kg) of the monotherapy arm, a monumental milestone was achieved: a complete response (CR) was induced in a patient with refractory bladder cancer who had previously shown zero response to conventional immune checkpoint inhibitors.
The patient's progression-free survival (PFS) was confirmed at 13.9 months a stellar figure that is more than double the previously reported PFS data (approximately 6 months) for Padcev, the current standard of care in clinical practice. Furthermore, a partial response (PR) was observed in a patient with immune-checkpoint-inhibitor-refractory malignant mesothelioma, further proving the candidate's anti-tumor activity.
The combination therapy arm with the global blockbuster drug Keytruda (pembrolizumab) is equally encouraging. In the clear cell renal cell carcinoma (ccRCC) cohort which holds the most accumulated data among the 48 solid tumor patients enrolled the combination yielded an impressive objective response rate (ORR) of 40% and a disease control rate (DCR) of 70%.
Even though 70% of the total patient population consisted of individuals who had already failed prior immunotherapy, the duration of response lasted for up to 16.7+ months. Since the majority of these patients are still ongoing with their treatment, there is a strong likelihood that the final PFS data will improve even further.
An official from GI Innovation stated, "GI-101A is proving a clear trend where anti-tumor activity increases in a dose-proportional manner. Even after the abstract submission deadline, overwhelming results exceeding prior data in terms of response durability and ORR are continuing to accumulate in real time. We look forward to revealing these highly encouraging findings at the ASCO site."
|
Orient Bio Rallies on Strong Responsible Governance Drive Post-Stock Merge and Progress on 3 Major Growth Strategies
Closing at 978 won a sharp 14.12% spike from the previous day Orient Bio (002630) saw its stock price strongly driven by an ambitious business structure upgrade declaration and momentum surrounding management's equity expansion. Following the completion of institutional adjustments, including a stock merge and the listing of new shares, the company officially announced detailed measures to enhance mid-to-long-term corporate value on the morning of June 11, successfully capturing the trust of savvy investors.
Orient Bio’s management explicitly diagnosed that the current stock price does not fully reflect the company's intrinsic asset value and independent future growth potential. Accordingly, they announced that the largest shareholder, special relationship parties, and affiliates are actively reviewing various methods to expand their stake within legal boundaries, including open-market purchases. This move was interpreted by the market as a powerful signal of the major shareholders' commitment to price stabilization and responsible governance, acting as a strong catalyst for buying.
The company presented three core pillars for its future growth trajectory. Specifically, these are: △the advancement of the innovative hair loss treatment candidate ‘OND-1’, △the expansion of the global non-human primate (NHP) core infrastructure business, and △the establishment of an artificial intelligence (AI)-driven next-generation bio platform. As a company that has long maintained a highly competitive edge in the laboratory animal production and preclinical research support markets, Orient Bio plans to seamlessly transplant its accumulated bio-infrastructure operational expertise into these new business engines.
OND-1, the centerpiece of the company's drug development division, is aggressively ramping up its research capabilities and R&D investment with the ultimate goal of clinical entry and commercialization. The laboratory animal segment is also poised for a major step up; with global demand for high-quality primates exploding in tandem with the boom in biopharmaceutical development, Orient Bio intends to proactively reinforce its overseas supply chain to elevate its global market dominance.
In parallel, the company is building a next-generation bio-digital platform that merges massive preclinical big data with AI algorithms. This strategy aims to maximize overall research efficiency by digitizing the drug candidate screening and preclinical testing processes, ultimately creating a new cash cow via a "Bio-Business-as-a-Service" model. Through these structural improvements and company-wide operational efficiency upgrades, the company made a concrete pledge to shareholders to secure a turnaround into profitability by the next fiscal year.
An official from Orient Bio remarked, "This is a process of fusing high-value-added territories like drug discovery and AI bio platforms onto the solid foundation of our highest-quality laboratory animal infrastructure business, which we do best. Rather than just relying on slogans, we will maximize mid-to-long-term corporate value through tangible outcomes that satisfy the market, alongside accountable management by our major shareholders."
|
L&C Bio Surges on Corporate Value Jump, Spurred by Re2O Market Penetration and High-Growth Expectations
L&C Bio, a company specializing in tissue regenerative medicine, closed at 84,000 won up 12.60% from the previous day as anticipation surrounding the financial growth of its extracellular matrix (ECM)-based innovative regenerative solution, ‘Re2O’, synergetically blended with positive global academic marketing achievements.
L&C Bio previously demonstrated its robust underlying potential through its Q1 earnings disclosure. The company's Q1 consolidated revenue skyrocketed by 70.6% year-on-year to 303 billion won, while operating profit reached 6.0 billion won, successfully turning a profit.
This milestone was achieved despite a heavy initial fixed-cost burden incurred by aggressively expanding production facilities and hiring a large number of quality-control personnel to meet the surging demand for Re2O. In fact, the company proved both top-line growth and operational efficiency simultaneously, posting an extraordinary consolidated operating profit margin of 19.8% and a standalone operating profit margin of 27.2%.
This performance signifies that Re2O has successfully achieved a soft landing in the premium medical market, established itself as the primary growth engine. Immediately following its launch, Re2O saw its adoption rate climb vertically through strong word-of-mouth among dermatologists and plastic surgeons. Moving beyond a trendy aesthetic product, it has taken on a pivotal role in restructuring L&C Bio's mid-to-long-term business model toward a high-margin configuration.
Market attention is now locked onto the production capacity (CAPA) expansion timeline required to support Re2O's steep sales growth trajectory. Currently, the company is progressively scaling up its production capabilities from the previous level of 35,000 units per month.
Having successfully secured a monthly production system of 80,000 units as of May, the company plans to radically expand its CAPA to 150,000 units per month starting this coming November. As the expanded volume hits the market in the second half of the year, the pace of revenue scale-up is expected to accelerate further. Combined with the company's existing flagship human tissue implant product, ‘Megaderm’ which continues to serve as a rock-solid cash cow backed by extensive clinical data and deep market trust L&C Bio has finalized an ideal portfolio that captures both stability and high growth.
The company's expansion into global territories is also progressing smoothly. L&C Bio announced that it successfully held an exclusive webinar for over 200 local medical professionals in Myanmar on June 11, focusing on Re2O, the world's first skin booster utilizing human acellular dermal matrix (hADM).
Held under the theme 'The ECM Revolution Begins', the seminar shared Re2O's clinical mechanism for fundamentally reversing skin aging by restoring the skin's natural ECM environment, alongside precise injection techniques utilizing the dedicated injector 'i-ject B'. The presentation drew enthusiastic praise from the Southeast Asian physicians in attendance.
An official from L&C Bio stated, "Re2O is just at the entry point of a massive global growth phase. By sophisticatedly upgrading our integrated platform strategy, we will establish an unrivaled global regenerative medicine ecosystem that encompasses everything from diagnosis and treatment to full tissue reconstruction.“
![손흥민·이강인으로 졌다고?…한국 탈락에 日냉정한 평가 [일본 엿보기]](https://image.edaily.co.kr/images/Photo/files/NP/S/2026/06/PS26063000540t.jpg)
